Table of Contents

• What is SAR421869?
• Usher Syndrome Type 1B: Understanding the Condition
• How SAR421869 Works
• Clinical Trial Details
• Potential Benefits of SAR421869
• Safety Considerations

What is SAR421869?

SAR421869 is an innovative medical treatment being developed for patients with Usher syndrome Type 1B. It is also known by several other names, including UshStat and “Lentiviral vector containing the human MYO7A gene”^[1]. This treatment is classified as a gene therapy, which means it aims to treat a genetic condition by introducing a corrective gene into the patient’s cells.

The full scientific name of SAR421869 is quite complex: “Lentiviral vector derived from the equine infectious anaemia virus containing the human MYO7A gene”^[1]. Let’s break this down:

• Lentiviral vector: This is a tool used to deliver genetic material into cells. It’s derived from a type of virus but modified to be safe for medical use.
• Equine infectious anaemia virus: This is the specific virus that the vector is based on. Don’t worry – it has been modified and can’t cause disease.
• Human MYO7A gene: This is the gene that the treatment delivers to cells. In people with Usher syndrome Type 1B, this gene is faulty, and the therapy aims to provide a working copy.

Usher Syndrome Type 1B: Understanding the Condition

Usher syndrome is a genetic condition that affects both hearing and vision. Type 1B is a specific form of this syndrome^[1]. People with Usher syndrome Type 1B are usually born with severe to profound hearing loss and begin to lose their vision in childhood due to an eye condition called retinitis pigmentosa. This vision loss is progressive, meaning it gets worse over time.

The condition is caused by mutations in the MYO7A gene, which provides instructions for making a protein important for the normal function of hair cells in the inner ear and light-sensitive cells (photoreceptors) in the retina of the eye^[1].

How SAR421869 Works

SAR421869 is designed to treat the underlying cause of Usher syndrome Type 1B. Here’s how it works:

1. The treatment contains a healthy copy of the MYO7A gene.
2. It is delivered directly to the retina through a procedure called a subretinal injection.
3. Once in the retina, the lentiviral vector helps the healthy MYO7A gene enter the cells.
4. The cells can then use this healthy gene to produce the correct protein, potentially slowing or stopping the progression of vision loss.

This approach is considered an advanced therapy, specifically a type of gene transfer product^[1]. It’s important to note that this treatment is focused on preserving vision and is not expected to improve hearing loss associated with Usher syndrome.

Clinical Trial Details

SAR421869 is currently being studied in a clinical trial to evaluate its long-term safety and effectiveness. Here are some key details about the trial^[1]:

• Trial Name: “A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B”
• Main Objective: To evaluate the long-term safety and tolerability of SAR421869
• Secondary Objective: To assess the long-term biological activity of SAR421869
• Eligibility: Participants must have been enrolled in a previous study (protocol TDU13600) and received a subretinal injection of SAR421869

The trial is designed to gather important information about how patients respond to the treatment over an extended period.

Potential Benefits of SAR421869

While the full benefits of SAR421869 are still being studied, the treatment has potential to^[1]:

• Delay retinal degeneration: This means it might slow down the loss of vision in people with Usher syndrome Type 1B.
• Provide long-term effects: The study is looking at the long-term biological activity of the treatment, which could mean lasting benefits for patients.

It’s important to remember that these potential benefits are still being researched and are not guaranteed.

Safety Considerations

As with any medical treatment, safety is a top priority in the development of SAR421869. The clinical trial is closely monitoring several safety aspects^[1]:

• Adverse events: The study is tracking any side effects or unexpected reactions to the treatment.
• Ocular safety: Researchers are watching for any important changes in eye health following treatment.

It’s worth noting that SAR421869 has been designated as an orphan drug by the European Union^[1]. This status is given to treatments for rare diseases and can help accelerate their development and approval process.

While SAR421869 shows promise, it’s still in the research phase. Patients with Usher syndrome Type 1B should consult with their healthcare providers about current treatment options and the possibility of participating in clinical trials.